Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charlotte M. Proby is active.

Publication


Featured researches published by Charlotte M. Proby.


Journal of Medical Virology | 2000

Human papillomavirus infection and non‐melanoma skin cancer in immunosuppressed and immunocompetent individuals

Catherine A. Harwood; T. Surentheran; Jane M. McGregor; Patricia J. Spink; Irene M. Leigh; Judith Breuer; Charlotte M. Proby

The role of human papillomavirus (HPV) in anogenital carcinogenesis is established firmly, but a similar role in non‐melanoma skin cancer remains speculative. Certain immunosuppressed individuals have an increased incidence of both viral warts and non‐melanoma skin cancer, that has prompted the suggestion that HPV may play a pathogenic role. Differences in the techniques used to detect HPV DNA in skin, however, have led to discrepancies in the prevalence and spectrum of HPV types reported in these malignancies. This study describes the use of a comprehensive degenerate PCR technique to compare the HPV status of 148 Non‐melanoma skin cancers from immunosuppressed and immunocompetent individuals. HPV DNA was detected in 37/44 (84.1%) squamous cell carcinomas, 18/24 (75%) basal cell carcinomas and 15/17 (88.2%) premalignant skin lesions from the immunosuppressed group compared with 6/22 (27.2%) squamous cell carcinomas, 11/30 (36.7%) basal cell carcinomas and 6/11 (54.4%) premalignancies in the immunocompetent group. Epidermodysplasia verruciformis HPV types prevailed in all lesion types from both groups of patients. In immunosuppressed individuals, cutaneous HPV types were also identified at high frequency, and co‐detection of multiple HPV types within single tumours was commonly observed. This study represents the largest and most comprehensive analysis of the HPV status of non‐melanoma skin cancers yet undertaken; whereas there are clearly significant differences in non‐melanoma skin cancers from immunosuppressed and immunocompetent populations, we provide evidence that the prevalence and spectrum of HPV types does not differ in squamous cell carcinomas, basal cell carcinomas or premalignancies within the two populations. These data have important implications for future investigation of the role of HPV in cutaneous carcinogenesis at a functional level. J. Med. Virol. 61:289–297, 2000.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma

Nicholas Wang; Zachary Sanborn; Kelly L. Arnett; Laura J. Bayston; Wilson Liao; Charlotte M. Proby; Irene M. Leigh; Eric A. Collisson; Patricia B. Gordon; Lakshmi Jakkula; Sally D. Pennypacker; Yong Zou; Mimansa Sharma; Jeffrey P. North; Swapna Vemula; Theodora M. Mauro; Isaac M. Neuhaus; Philip E. LeBoit; Joe S Hur; Kyung-Hee Park; Nam Huh; Pui-Yan Kwok; Sarah T. Arron; Pierre P. Massion; Allen E. Bale; David Haussler; James E. Cleaver; Joe W. Gray; Paul T. Spellman; Andrew P. South

Squamous cell carcinomas (SCCs) are one of the most frequent forms of human malignancy, but, other than TP53 mutations, few causative somatic aberrations have been identified. We identified NOTCH1 or NOTCH2 mutations in ∼75% of cutaneous SCCs and in a lesser fraction of lung SCCs, defining a spectrum for the most prevalent tumor suppressor specific to these epithelial malignancies. Notch receptors normally transduce signals in response to ligands on neighboring cells, regulating metazoan lineage selection and developmental patterning. Our findings therefore illustrate a central role for disruption of microenvironmental communication in cancer progression. NOTCH aberrations include frameshift and nonsense mutations leading to receptor truncations as well as point substitutions in key functional domains that abrogate signaling in cell-based assays. Oncogenic gain-of-function mutations in NOTCH1 commonly occur in human T-cell lymphoblastic leukemia/lymphoma and B-cell chronic lymphocytic leukemia. The bifunctional role of Notch in human cancer thus emphasizes the context dependency of signaling outcomes and suggests that targeted inhibition of the Notch pathway may induce squamous epithelial malignancies.


Current Opinion in Infectious Diseases | 2002

Human papillomaviruses and non-melanoma skin cancer.

Catherine A. Harwood; Charlotte M. Proby

Epidemiological and experimental studies have overwhelmingly confirmed human papillomaviruses as important causal agents in anogenital carcinogenesis. A role for human papillomaviruses has also been proposed in a diverse range of other malignancies, and particular interest has focused on non-melanoma skin cancer, the commonest malignancy in fair-skinned populations worldwide. Although the evidence for this is considerably less convincing than for anogenital cancer, important epidemiological and functional data have emerged over the past year that have furthered our understanding of the possible contribution of human papillomaviruses to skin cancer. Epidemiological human papillomavirus DNA detection studies have shown associations with non-melanoma skin cancer, but have also emphasized the ubiquity of epidermodysplasia verruciformis human papillomavirus types in normal skin, hair follicles and benign hyperproliferative disorders, as have seroepidemiological approaches. Functional investigations have demonstrated mechanistically relevant interactions between the virus and ultraviolet radiation, host cytokines and cellular proteins including p53 and the pro-apoptotic protein Bak. Taken together, these data have advanced our understanding of the contribution of human papillomaviruses to malignant transformation in cutaneous keratinocytes, but further research is required before a causal association between human papillomaviruses and skin cancer is reliably confirmed.


British Journal of Dermatology | 2007

Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.

C. Ulrich; J. Bichel; S. Euvrard; B. Guidi; Charlotte M. Proby; P.C.M. van de Kerkhof; P. Amerio; J. Rønnevig; H.B. Slade; Eggert Stockfleth

Objective  In this study the safety and efficacy of imiquimod 5% cream for the treatments of actinic keratoses in kidney, heart and liver transplant recipients is evaluated.


Journal of Investigative Dermatology | 2014

NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis

Andrew P. South; Karin J. Purdie; Stephen Watt; Sam Haldenby; Nicoline Y. den Breems; Michelle T. Dimon; Sarah T. Arron; Michael J. Kluk; Angela McHugh; Dylan J. Xue; Jasbani H.S. Dayal; Kim S. Robinson; Sm Hasan Rizvi; Charlotte M. Proby; Catherine A. Harwood; Irene M. Leigh

Cutaneous SCC (cSCC) is the most frequent skin cancer with metastatic potential and can manifest rapidly as a common side effect in patients receiving systemic kinase inhibitors. Here we use massively parallel exome and targeted level sequencing 132 sporadic cSCC, 39 squamoproliferative lesions and cSCC arising in patients receiving the BRAF inhibitor vemurafenib, as well as 10 normal skin samples to identify significant NOTCH1 mutation as an early event in squamous cell carcinogenesis. Bisected vemurafenib induced lesions revealed surprising heterogeneity with different activating HRAS and NOTCH1 mutations identified in two halves of the same cSCC suggesting polyclonal origin. Immunohistochemical analysis using an antibody specific to nuclear NOTCH1 correlates with mutation status in sporadic cSCC and regions of NOTCH1 loss or down-regulation are frequently observed in normal looking skin. Our data indicate that NOTCH1 acts as a gatekeeper in human cSCC.


Cancer Research | 2010

Multicenter Study of the Association between Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma

Jan Nico Bouwes Bavinck; Rachel E. Neale; Damiano Abeni; Sylvie Euvrard; Adèle C. Green; Catherine A. Harwood; Maurits N. C. de Koning; Luigi Naldi; Ingo Nindl; Michael Pawlita; Herbert Pfister; Charlotte M. Proby; Wim Quint; Jan ter Schegget; Tim Waterboer; Sönke Weissenborn

Human papillomaviruses (betaPV) from the beta genus cannot be classified according to their oncogenicity due to a paucity of information. This study evaluates the association between betaPV infection and cutaneous squamous cell carcinoma in conjunction with measures of UV exposure and susceptibility. We performed case-control studies in the Netherlands, Italy, and Australia, countries with profoundly different UV exposures. The presence of 25 betaPV types in eyebrow hair follicles was determined using a highly sensitive HPV DNA genotyping assay, and antibodies for the 15 most prevalent betaPV types in a total of 689 squamous cell carcinoma cases and 845 controls were detected using multiplex serology. Multivariate logistic regression models were used for case-control comparisons and interaction analyses. BetaPV DNA was detected in eyebrow hairs of more than 90% of all participants. The presence of betaPV DNA was associated with an increased risk of squamous cell carcinoma in the Netherlands (OR = 2.8; 95% CI 1.3-5.8) and Italy (OR = 1.7; 95% CI 0.79-3.6), but not in Australia (OR = 0.91; 95% CI 0.53-1.6). Seropositivity for betaPV in controls ranged between 52% and 67%. A positive antibody response against 4 or more betaPV types was associated with squamous cell carcinoma in Australia (OR = 2.2; 95% CI 1.4-3.3), the Netherlands (OR = 2.0; 95% CI 1.2-3.4) and fair-skinned Italians (OR = 1.6, 95% CI 0.94- 2.7). The association between UV susceptibility and squamous cell carcinoma was stronger in betaPV-seropositive people. These combined data support the hypothesis that betaPV may play a role in the development of cutaneous squamous cell carcinoma.


American Journal of Transplantation | 2011

A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients

Charlotte M. Proby; Catherine A. Harwood; Rachel E. Neale; Adèle C. Green; Sylvie Euvrard; Luigi Naldi; Gianpaolo Tessari; M.N.C. de Koning; Wim Quint; Tim Waterboer; Michael Pawlita; Sönke Weissenborn; Ulrike Wieland; Herbert Pfister; Eggert Stockfleth; Ingo Nindl; Damiano Abeni; J. ter Schegget; J.N. Bouwes Bavinck

We examined the association between betapapillomavirus (betaPV) infection and cutaneous squamous cell carcinoma (SCC) in organ transplant recipients. A total of 210 organ transplant recipients with previous SCC and 394 controls without skin cancer were included. The presence of 25 betaPV types in plucked eyebrow hairs was determined using a human papillomavirus (HPV) DNA genotyping assay, and antibodies for the 15 most prevalent betaPV types were detected using multiplex serology. We used multivariate logistic regression models to estimate associations between various measures of betaPV infection and SCC. BetaPV DNA was highly prevalent (>94%) with multiple types frequently detected in both groups. We found a significant association between SCC and the concordant detection of both antibodies and DNA for at least one betaPV type (adjusted OR 1.6; 95% CI 1.1;2.5). A borderline‐significant association with SCC was found for HPV36 (adjusted OR 2.4; CI 1.0;5.4), with similar associations for HPV5, HPV9 and HPV24. These data provide further evidence of an association between betaPV infection and SCC in organ transplant recipients. Confirmation of a betaPV profile predictive of risk for SCC may pave the way for clinically relevant pretransplant HPV screening and the development of preventive and therapeutic HPV vaccination.


The EMBO Journal | 1999

The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence

Karin J. Purdie; Joanne Pennington; Charlotte M. Proby; Sahira Khalaf; Ethel Michelle De Villiers; Irene M. Leigh; Alan Storey

An aetiological role has been proposed for human papillomavirus (HPV) in skin carcinogenesis within the immunosuppressed patient population. To examine this possibility, we have focused on an HPV type that, to date, has been identified only in the cutaneous lesions of renal transplant recipients despite a high degree of sequence homology with other HPVs commonly found in warts in the general population. We report that the non‐coding region of this virus, HPV type 77, contains a consensus binding site for the tumour suppressor protein p53, and we show by gel‐retardation analysis that this sequence does indeed bind p53. Furthermore, using reporter gene assays, we demonstrate that HPV77 promoter activity is stimulated by UV radiation and that this response is mediated through the p53 binding site. This is the first report of a p53‐dependent positive response element within a viral genome. Our results suggest a possible novel mechanism by which specific types of HPV might act as cofactors with UV radiation in cutaneous transformation.


Journal of Clinical Oncology | 2013

Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus

Judith M. Hoogendijk-van den Akker; Paul N. Harden; Andries J. Hoitsma; Charlotte M. Proby; Ron Wolterbeek; Jan Nico Bouwes Bavinck; Johan W. de Fijter

PURPOSE In light of the significant morbidity and mortality of cutaneous invasive squamous cell carcinomas (SCCs) in renal transplant recipients, we investigated whether conversion to sirolimus-based immunosuppression from standard immunosuppression could diminish the recurrence rate of these skin cancers. PATIENTS AND METHODS In a 2-year randomized controlled trial, 155 renal transplant recipients with at least one biopsy-confirmed SCC were stratified according to age (< 55 v ≥ 55 years) and number of previous SCCs (one to nine v ≥ 10) and randomly assigned to conversion to sirolimus (n = 74) or continuation of their original immunosuppression (n = 81). Development of a new SCC within 2 years after random assignment was the primary end point. RESULTS After 2 years of follow-up, the risk reduction of new SCCs in the multivariable analysis was not significant, with a hazard ratio (HR) of 0.76 (95% CI, 0.48 to 1.2; P = .255), compared with a non-sirolimus-based regimen. After the first year, there was a significant 50% risk reduction, with an HR of 0.50 (95% CI, 0.28 to 0.90; P = .021) for all patients together and an HR of 0.11 (95% CI, 0.01 to 0.94; P = .044) for patients with only one previous SCC. The tumor burden of SCC was reduced during the 2-year follow-up period in those receiving sirolimus (0.82 v 1.38 per year; HR, 0.51; 95% CI, 0.32 to 0.82; P = .006) if adjusted for the number of previous SCCs and age. Twenty-nine patients stopped taking sirolimus because of various adverse events. CONCLUSION Conversion to sirolimus-based immunosuppression failed to show a benefit in terms of SCC-free survival at 2 years.


Journal of General Virology | 2009

Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma.

Maurits N. C. de Koning; Sönke Weissenborn; Damiano Abeni; Jan Nico Bouwes Bavinck; Sylvie Euvrard; Adèle C. Green; Catherine A. Harwood; Luigi Naldi; Rachel E. Neale; Ingo Nindl; Charlotte M. Proby; Wim Quint; Francesca Sampogna; Jan ter Schegget; Linda Struijk; Ulrike Wieland; Herbert Pfister

Betapapillomavirus (betaPV) infections are often associated with squamous-cell carcinoma (SCC) and the prevalence of betaPV infections in (immunosuppressed) SCC patients is known to be high. The distribution and possible associated factors of betaPV infections in the general population, however, are largely unknown. To address this issue, betaPV infection was studied in 1405 SCC-free immunocompetent (n=845) and immunosuppressed (n=560) individuals from six countries of different latitudes. A standard study protocol was used to obtain information about age, sex, UV-irradiation and skin type, and from all participants eyebrow hairs were collected for detection and genotyping of 25 established betaPV types using the PM-PCR reverse hybridization assay (RHA) method. The frequency of betaPV-positive participants ranged from 84 to 91% in the immunocompetent population with HPV23 as the most prevalent type, and from 81 to 98% in the immunosuppressed population with HPV23 as the most or the second most prevalent type. The median number of infecting betaPV types ranged from four to six in the immunocompetent and from three to six in the immunosuppressed population. Increasing age in the immunocompetent participants and (duration of) immunosuppression in the immunosuppressed patients were associated with betaPV infection. In both groups, sex, skin phototype, sunburns and sun-exposure were not consistently associated with betaPV infection. This study demonstrates that betaPV infections are also highly prevalent in SCC-free individuals, with similar HPV types prevailing in both immunocompetent and immunosuppressed persons. Age and (duration of) immunosuppression were identified as betaPV infection-associated factors, whereas characteristics related to sun exposure and skin type were not.

Collaboration


Dive into the Charlotte M. Proby's collaboration.

Top Co-Authors

Avatar

Catherine A. Harwood

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Irene M. Leigh

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Karin J. Purdie

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Jane M. McGregor

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Andrew P. South

Thomas Jefferson University

View shared research outputs
Top Co-Authors

Avatar

Jan Nico Bouwes Bavinck

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Tim Waterboer

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael Pawlita

German Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge